Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Overview of attention for article published in American Journal of Hematology, February 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter: 6 X users
patent: 3 patents

wikipedia: 2 Wikipedia pages

Readers on

mendeley: 83 Mendeley

So far, Altmetric has seen 7 X posts from 6 X users, with an upper bound of 9,640 followers.

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. #lymphoma #lymsm https://t.co/zSLxhSfEFb

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. #lymphoma #lymsm https://t.co/qF3ltgz58Q

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. https://t.co/YbSs6bOCSI

#Urelumab alone or in combination with #rituximab in patients with relapsed or refractory B-cell #lymphoma . https://t.co/8kniWy0Zdc

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.